Loading...

1,267 posters, 47 videos, 13 topics, 4 sessions, 853 authors

ePostersLive by SciGen Technologies S.A. All rights reserved.

SOHO 2026 Annual Meeting

September 9 - 12, 2026 | George R. Brown Convention Center, Houston, Texas

Topics

Showing 230 results.

Thumbnail for Molecular Subtype-Specific Risk of Subsequent Acute Myeloid Leukemia Following Breast Cancer: A Population-Based SEER Analysis

AML - 1464

Molecular Subtype-Specific Risk of Subsequent Acute Myeloid Leukemia Following Breast Cancer: A Population-Based SEER Analysis

Maryam Ali

Poster Presenter: Maryam Ali

Thumbnail for Defining the “Frailty Cliff": A Restricted Cubic Spline Meta-Analysis of AI-Derived Continuous Mesenteric Adiposity and Skeletal Muscle Index on Induction Mortality in Acute Myeloid Leukemia

AML - 1473

Defining the “Frailty Cliff": A Restricted Cubic Spline Meta-Analysis of AI-Derived Continuous Mesenteric Adiposity and Skeletal Muscle Index on Induction Mortality in Acute Myeloid Leukemia

Iman Khan

Poster Presenter: Iman Khan

Thumbnail for Lower-Intensity Versus Intensive Therapy in Older Adults With Newly Diagnosed AML: A Systematic Review and Meta-Analysis

AML - 1475

Lower-Intensity Versus Intensive Therapy in Older Adults With Newly Diagnosed AML: A Systematic Review and Meta-Analysis

Musa Kiyani

Poster Presenter: Musa Kiyani

Thumbnail for Differential Impact of Allogeneic Stem Cell Transplantation by TP53 Mutational Status in High-Risk Myeloid Neoplasms With Complex or Monosomal Karyotype

AML - 1476

Differential Impact of Allogeneic Stem Cell Transplantation by TP53 Mutational Status in High-Risk Myeloid Neoplasms With Complex or Monosomal Karyotype

Paloma Resende

Poster Presenter: Paloma Resende

Thumbnail for Early Cytarabine Escalation Does Not Improve Short-Term Outcomes Compared With Hydroxyurea-Only Cytoreduction in Hyperleukocytic Acute Myeloid Leukemia: A Real-World Propensity-Matched Analysis

AML - 1478

Early Cytarabine Escalation Does Not Improve Short-Term Outcomes Compared With Hydroxyurea-Only Cytoreduction in Hyperleukocytic Acute Myeloid Leukemia: A Real-World Propensity-Matched Analysis

Akshay Aluri

Poster Presenter: Akshay Aluri

Thumbnail for Multi-Hit TET2 Inactivation Identifies a High-Risk Subgroup Assigned to Favorable or Intermediate Categories by the HARMONY Framework in NPM1-Mutated AML

AML - 1483

Multi-Hit TET2 Inactivation Identifies a High-Risk Subgroup Assigned to Favorable or Intermediate Categories by the HARMONY Framework in NPM1-Mutated AML

Paloma Resende

Poster Presenter: Paloma Resende

Thumbnail for Temporal Decline in Early Mortality in Acute Myeloid Leukemia Across Chemotherapy, Hypomethylating Agent, and Venetoclax-Based Therapeutic Eras: A Four-Decade Population-Based Analysis

AML - 1492

Temporal Decline in Early Mortality in Acute Myeloid Leukemia Across Chemotherapy, Hypomethylating Agent, and Venetoclax-Based Therapeutic Eras: A Four-Decade Population-Based Analysis

Shahzaib Maqbool

Poster Presenter: Shahzaib Maqbool

Thumbnail for CRISPR/Cas9-Mediated SHP2 Knockout in Jurkat T Cells Using Neon and MaxCyte Electroporation Platforms: Establishment and Validation of a Model for SHP2-Driven Resistance Mechanisms

AML - 150

CRISPR/Cas9-Mediated SHP2 Knockout in Jurkat T Cells Using Neon and MaxCyte Electroporation Platforms: Establishment and Validation of a Model for SHP2-Driven Resistance Mechanisms

Kashif Ali

Poster Presenter: Kashif Ali

Thumbnail for Age-, Sex-, Race-, and Ethnicity-Dependent Architecture of the AML DriverMutational Landscape: A Real-World Analysis of 5,111 Patients in AACRProject GENIE v18.0

AML - 1509

Age-, Sex-, Race-, and Ethnicity-Dependent Architecture of the AML DriverMutational Landscape: A Real-World Analysis of 5,111 Patients in AACRProject GENIE v18.0

Nency Ganatra

Poster Presenter: Nency Ganatra

This website and third-party tools we use rely on cookies for the best user experience. By selecting "I agree", you agree to cookie usage as described in our Privacy Policy.